ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE

Also written as “NLG802 (indoximod Prodrug)” and “NLG802”.

Its studies are mostly in Brain Neoplasms, led by Lumos Pharma.

Drug pageEthyl LEUCYL-1-METHYL-D-TRYPTOPHANATE: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since May 22, 20172 company-led studies, 1 open or runningNext primary completion: Oct 8, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lumos Pharma21 open or runningphase 1since May 22, 2017May 22, 2017Oct 8, 2030phase 1 · NCT07732413

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2017First study: phase 1 study in Solid TumorFirst studyNCT03164603 · 26 enrolled · United States
  2. Jul 20, 2026Phase 1 study in Progressive Pediatric Brain CancerNCT07732413 · 30 planned · United States

Ahead

  1. Oct 8, 2030Primary completion: phase 1 study in Progressive Pediatric Brain CancerNCT07732413

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07732413Progressive Pediatric Brain Cancer · United States1Not yet recruitingOct 8, 203030
NCT03164603Solid Tumor · United States1CompletedApr 1, 201926

How it is read

Names in the registry

  • “NLG802 (indoximod Prodrug)”, 1 entry
  • “NLG802”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.